Monoamine Oxidase A (MAO-A) Rat Binding Antagonist Radioligand LeadHunter Assay - FR

Item: 443

Price: Login to View Pricing

Status: Available

ADD TO CART

OVERVIEW

DOCUMENTS/REFERENCES

Biological Information

Background Information:

Monoamine Oxidase (MAO, E.C.1.4.3.4) catalyzes the removal of an amine group from a variety of substrates including endogenous substances (norepinephrine, epinephrine, dopamine, tyramine, 5-hydroxytryptamine) and many drugs that are amines. MAO functions as an important protective mechanism against exogenous, biologically active amines. There are at least two types of MAO which display dissimilar preferences for substrates and differential sensitivities to selective inhibitors.

Family:

Neurotransmitter Metabolism

Sub Family:

Catecholamine Turnover

Protein Name:

MAO-A

Uniprot Number:

P21397 (human)

Gene Name:

MAOA

Gene ID:

4128

Accession Number:

NM_000240

Organism:

Rat

Tissue:

Brain

Assay Information

Assay Type:

Biochemical

Assay Sub Type:

Binding

Detection Method:

Radiometric

Measured Response:

Scintillation

Testing Information

Ligand:

[3H]Ro 41-1049

Ligand Kd (nM):

Ligand Concentration:

10 nM

Non Specific:

1 µM Clorgyline

Incubation:

60 min at 37°C

Control Inhibitor:

Clorgiline

Test Concentration / Dose:

Eurofins will provide IC/EC50 calculation if 5 or more concentrations are selected.

Test Sample Requirements:

Minimum for 1) Screen: 60 µl of 10 mM stock -OR- 1 mg (pre-weighed) for 10µM final testing. 2) Dose Response: 90 µl of 10 mM stock -OR- 1 mg (pre-weighed) for a top concentration at 10 µM.

Minimum Order Quantity:

Turnaround Time

Standard:

10 Business Days

Reference Compound Data

PubChem ID

4289

Name

N-(2-aminoethyl)-4-chlorobenzamide

Measurement

60000nM - IC50

PubChem ID

4380

Name

Clorgiline

Measurement

1.1nM - IC50

PubChem ID

Name

Ro 41-1049

Measurement

44nM - IC50

PubChem ID

Name

(R)-deprenyl

Measurement

1800nM - IC50

Clinical Relevance

Therapeutic Area:

CNS/Addiction/Pain

Adverse / Beneficial Action:

Selective inhibitors of MAO-A (e.g. clorgyline) appear to have efficacy in the treatment of major depression, and a selective MAO-B inhibitor may have beneficial effect on Parkinsons disease and dyskinesia.

Additional Information

Brand:

LeadHunter

Testing Location:

France - Celle L'Evescault